Search
Palopegteriparatide
go.drugbank.com/drugs/DB18676ApprovedInvestigational[L51134] PTH(1-34) contains the N-terminal part of the endogenous PTH molecule. … [L51134] Palopegteriparatide was first approved by the EMA on November 17, 2023, for the treatment of hyperparathyroidism.[L51134] On August 8, 2024, palopegteriparatide was also approved by the FDA.
Synonyms: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34, Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-L-seryl-L-valyl-L-seryl-L-α-glutamyl-L-isoleCoenzyme M
go.drugbank.com/drugs/DB09110ApprovedInvestigationalCoenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
Categories: Compounds used in a research, industrial, or household settingFremanezumab
go.drugbank.com/drugs/DB14041ApprovedInvestigational[L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and the oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment … [L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018.
Products: AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5ML, Ajovy Filled PenSeladelpar
go.drugbank.com/drugs/DB12390ApprovedInvestigational[L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism
Lenalidomide
go.drugbank.com/drugs/DB00480ApprovedInvestigationalzone lymphoma in selected patients. … [A228708] Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal
Acetarsol
go.drugbank.com/drugs/DB13268ApprovedWithdrawn[L2622] It was first discovered in 1921 by Ernest Fourneau at the Pasteur Institute. It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964. … Acetarsol, with the molecular formula N-acetyl-4-hydroxy-m-arsanilic acid, is a pentavalent arsenical compound with antiprotozoal and antihelmintic properties.
Sulfur hexafluoride
go.drugbank.com/drugs/DB11104ApprovedInvestigationalin adult patients with suboptimal echocardiograms •in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients … Sulfur hexafluoride is an ultrasound contrast agent indicated for use •in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border
Scopolamine
go.drugbank.com/drugs/DB00747ApprovedInvestigational[A228763] As an acetylcholine analogue, scopolamine can antagonize muscarinic acetylcholine receptors (mAChRs) in the central nervous system and throughout the body, inducing several therapeutic and adverse … [A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient than extracting scopolamine from plants.
Odevixibat
go.drugbank.com/drugs/DB16261ApprovedInvestigationalOdevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC … [A236808] Odevixibat was granted FDA and Health Canada approval on 20 July 2021 and 13 November 2023 respectively.[L34793,L49535]
Belimumab
go.drugbank.com/drugs/DB08879ApprovedInvestigational[L42630] Belimumab was first approved by the FDA on March 9, 2011,[A251495] making it the newest drug to be approved for the treatment of SLE in more than 50 years. … It is produced by recombinant DNA technology in a murine cell (NS0) expression system.